Answers are grounded in this paper and cite their sources.
The American Cancer Society (ACS), in 2003, found that nonconventional screening measures such as magnetic resonance imaging (MRI) might be suitable for women at increased risk of breast cancer, but there was not enough evidence to warrant making recommendations. Since then, more information on MRI screening has become available, and an expert panel has been convened to review this evidence and develop recommendations for women predicated on their risk level. MRI with contrast enhancement has been widely used to evaluate symptomatic disease, and found to be a sensitive screening tool in women having a family history of breast cancer. The use of dedicated breast MRI coils ensures higher-quality images. Other risk factors are mantle field radiotherapy for Hodgkin disease and the presence of lobular carcinoma in situ, atypical lobular hyperplasia, or atypical ductal hyperplasia. Mammographic density is a strong independent risk factor for breast cancer. Studies have shown sensitivity rates of 71% to 100% for MRI screening, compared to 16% to 40% for mammography. Nevertheless, false-negative results do occur, and MRI has been significantly less specific than mammography in all studies done to date. Rates of call-back for further imaging range from 8% to 17% in MRI screening studies, and biopsy rates from 3% to 15%. The value of MRI depends to a significant degree on high-quality imaging and on expert interpretation. Data on the cost-effectiveness of breast MRI screening are limited. The ACS now recommends screening MRI for women whose lifetime risk of breast cancer is estimated to be 20% to 25% or greater. They include women with a strong family history of breast or ovarian cancer and those treated for Hodgkin disease. These recommendations assume an acceptable level of MRI quality, performed by experienced persons at facilities that provide MRI-guided biopsy to follow up suspicious findings. Insufficient data are available to make recommendations for women who have a personal history of breast cancer, carcinoma in situ, atypical hyperplasia, or very dense breasts on mammography.
No takes yet. Share an insight, caveat, or question.
Saslow et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: